King's College London

Research portal

Circulating Sex Hormone Levels and Risk of Esophageal Adenocarcinoma in a Prospective Study in Men

Research output: Contribution to journalArticle

Standard

Circulating Sex Hormone Levels and Risk of Esophageal Adenocarcinoma in a Prospective Study in Men. / Xie, Shao Hua; Ness-Jensen, Eivind; Rabbani, Sirus; Langseth, Hilde; Gislefoss, Randi E.; Mattsson, Fredrik; Lagergren, Jesper.

In: The American Journal of Gastroenterology, Vol. 115, No. 2, 01.02.2020, p. 216-223.

Research output: Contribution to journalArticle

Harvard

Xie, SH, Ness-Jensen, E, Rabbani, S, Langseth, H, Gislefoss, RE, Mattsson, F & Lagergren, J 2020, 'Circulating Sex Hormone Levels and Risk of Esophageal Adenocarcinoma in a Prospective Study in Men', The American Journal of Gastroenterology, vol. 115, no. 2, pp. 216-223. https://doi.org/10.14309/ajg.0000000000000446

APA

Xie, S. H., Ness-Jensen, E., Rabbani, S., Langseth, H., Gislefoss, R. E., Mattsson, F., & Lagergren, J. (2020). Circulating Sex Hormone Levels and Risk of Esophageal Adenocarcinoma in a Prospective Study in Men. The American Journal of Gastroenterology, 115(2), 216-223. https://doi.org/10.14309/ajg.0000000000000446

Vancouver

Xie SH, Ness-Jensen E, Rabbani S, Langseth H, Gislefoss RE, Mattsson F et al. Circulating Sex Hormone Levels and Risk of Esophageal Adenocarcinoma in a Prospective Study in Men. The American Journal of Gastroenterology. 2020 Feb 1;115(2):216-223. https://doi.org/10.14309/ajg.0000000000000446

Author

Xie, Shao Hua ; Ness-Jensen, Eivind ; Rabbani, Sirus ; Langseth, Hilde ; Gislefoss, Randi E. ; Mattsson, Fredrik ; Lagergren, Jesper. / Circulating Sex Hormone Levels and Risk of Esophageal Adenocarcinoma in a Prospective Study in Men. In: The American Journal of Gastroenterology. 2020 ; Vol. 115, No. 2. pp. 216-223.

Bibtex Download

@article{a5e640f382e648abb0716497fb8113ef,
title = "Circulating Sex Hormone Levels and Risk of Esophageal Adenocarcinoma in a Prospective Study in Men",
abstract = "OBJECTIVES: Sex hormones have been hypothesized to explain the strong male predominance in esophageal adenocarcinoma, but evidence is needed. This study examined how circulating sex hormone levels influence future risk of esophageal adenocarcinoma. METHODS: This case-control study was nested in a prospective Norwegian cohort (Janus Serum Bank Cohort), including 244 male patients with esophageal adenocarcinoma and 244 male age-matched control participants. Associations between prediagnostic circulating levels of 12 sex hormones and risk of esophageal adenocarcinoma were assessed using conditional logistic regression. In addition, a random-effect meta-analysis combined these data with a similar prospective study for 5 sex hormones. RESULTS: Decreased odds ratios (ORs) of esophageal adenocarcinoma were found comparing the highest with lowest quartiles of testosterone (OR = 0.44, 95{\%} confidence interval [CI] 0.22-0.88), testosterone:estradiol ratio (OR = 0.37, 95{\%} CI 0.19-0.72), and luteinizing hormone (OR = 0.50, 95{\%} CI 0.30-0.98), after adjustment for tobacco smoking and physical activity. These associations were attenuated after further adjustment for body mass index (OR = 0.56, 95{\%} CI 0.27-1.13 for testosterone; OR = 0.46, 95{\%} CI 0.23-0.91 for testosterone:estradiol ratio; OR = 0.55, 95{\%} CI 0.29-1.08 for luteinizing hormone). No associations were observed for sex hormone-binding globulin, dehydroepiandrosterone sulfate, follicle-stimulating hormone, prolactin, 17-OH progesterone, progesterone, androstenedione, or free testosterone index. The meta-analysis showed an inverse association between testosterone levels and risk of esophageal adenocarcinoma (pooled OR for the highest vs lowest quartile = 0.60, 95{\%} CI 0.38-0.97), whereas no associations were identified for androstenedione, sex hormone-binding globulin, estradiol, or testosterone:estradiol ratio. DISCUSSION: Higher circulating testosterone levels may decrease the risk of esophageal adenocarcinoma in men.",
author = "Xie, {Shao Hua} and Eivind Ness-Jensen and Sirus Rabbani and Hilde Langseth and Gislefoss, {Randi E.} and Fredrik Mattsson and Jesper Lagergren",
year = "2020",
month = "2",
day = "1",
doi = "10.14309/ajg.0000000000000446",
language = "English",
volume = "115",
pages = "216--223",
journal = "The American Journal of Gastroenterology",
issn = "1572-0241",
number = "2",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Circulating Sex Hormone Levels and Risk of Esophageal Adenocarcinoma in a Prospective Study in Men

AU - Xie, Shao Hua

AU - Ness-Jensen, Eivind

AU - Rabbani, Sirus

AU - Langseth, Hilde

AU - Gislefoss, Randi E.

AU - Mattsson, Fredrik

AU - Lagergren, Jesper

PY - 2020/2/1

Y1 - 2020/2/1

N2 - OBJECTIVES: Sex hormones have been hypothesized to explain the strong male predominance in esophageal adenocarcinoma, but evidence is needed. This study examined how circulating sex hormone levels influence future risk of esophageal adenocarcinoma. METHODS: This case-control study was nested in a prospective Norwegian cohort (Janus Serum Bank Cohort), including 244 male patients with esophageal adenocarcinoma and 244 male age-matched control participants. Associations between prediagnostic circulating levels of 12 sex hormones and risk of esophageal adenocarcinoma were assessed using conditional logistic regression. In addition, a random-effect meta-analysis combined these data with a similar prospective study for 5 sex hormones. RESULTS: Decreased odds ratios (ORs) of esophageal adenocarcinoma were found comparing the highest with lowest quartiles of testosterone (OR = 0.44, 95% confidence interval [CI] 0.22-0.88), testosterone:estradiol ratio (OR = 0.37, 95% CI 0.19-0.72), and luteinizing hormone (OR = 0.50, 95% CI 0.30-0.98), after adjustment for tobacco smoking and physical activity. These associations were attenuated after further adjustment for body mass index (OR = 0.56, 95% CI 0.27-1.13 for testosterone; OR = 0.46, 95% CI 0.23-0.91 for testosterone:estradiol ratio; OR = 0.55, 95% CI 0.29-1.08 for luteinizing hormone). No associations were observed for sex hormone-binding globulin, dehydroepiandrosterone sulfate, follicle-stimulating hormone, prolactin, 17-OH progesterone, progesterone, androstenedione, or free testosterone index. The meta-analysis showed an inverse association between testosterone levels and risk of esophageal adenocarcinoma (pooled OR for the highest vs lowest quartile = 0.60, 95% CI 0.38-0.97), whereas no associations were identified for androstenedione, sex hormone-binding globulin, estradiol, or testosterone:estradiol ratio. DISCUSSION: Higher circulating testosterone levels may decrease the risk of esophageal adenocarcinoma in men.

AB - OBJECTIVES: Sex hormones have been hypothesized to explain the strong male predominance in esophageal adenocarcinoma, but evidence is needed. This study examined how circulating sex hormone levels influence future risk of esophageal adenocarcinoma. METHODS: This case-control study was nested in a prospective Norwegian cohort (Janus Serum Bank Cohort), including 244 male patients with esophageal adenocarcinoma and 244 male age-matched control participants. Associations between prediagnostic circulating levels of 12 sex hormones and risk of esophageal adenocarcinoma were assessed using conditional logistic regression. In addition, a random-effect meta-analysis combined these data with a similar prospective study for 5 sex hormones. RESULTS: Decreased odds ratios (ORs) of esophageal adenocarcinoma were found comparing the highest with lowest quartiles of testosterone (OR = 0.44, 95% confidence interval [CI] 0.22-0.88), testosterone:estradiol ratio (OR = 0.37, 95% CI 0.19-0.72), and luteinizing hormone (OR = 0.50, 95% CI 0.30-0.98), after adjustment for tobacco smoking and physical activity. These associations were attenuated after further adjustment for body mass index (OR = 0.56, 95% CI 0.27-1.13 for testosterone; OR = 0.46, 95% CI 0.23-0.91 for testosterone:estradiol ratio; OR = 0.55, 95% CI 0.29-1.08 for luteinizing hormone). No associations were observed for sex hormone-binding globulin, dehydroepiandrosterone sulfate, follicle-stimulating hormone, prolactin, 17-OH progesterone, progesterone, androstenedione, or free testosterone index. The meta-analysis showed an inverse association between testosterone levels and risk of esophageal adenocarcinoma (pooled OR for the highest vs lowest quartile = 0.60, 95% CI 0.38-0.97), whereas no associations were identified for androstenedione, sex hormone-binding globulin, estradiol, or testosterone:estradiol ratio. DISCUSSION: Higher circulating testosterone levels may decrease the risk of esophageal adenocarcinoma in men.

UR - http://www.scopus.com/inward/record.url?scp=85079021588&partnerID=8YFLogxK

U2 - 10.14309/ajg.0000000000000446

DO - 10.14309/ajg.0000000000000446

M3 - Article

C2 - 31658123

VL - 115

SP - 216

EP - 223

JO - The American Journal of Gastroenterology

JF - The American Journal of Gastroenterology

SN - 1572-0241

IS - 2

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454